OS Therapies (OSTX) Preferred Stock Liabilities (2024 - 2026)
OS Therapies' (OSTX) quarterly Preferred Stock Liabilities came in at $1.1 million in Q1 2026, down 77.69% YoY from $4.8 million in Q1 2025, and little changed on a QoQ basis from $1.1 million in Q4 2025.
OS Therapies (OSTX) Preferred Stock Liabilities (2024 - 2026) Analysis & Trends
OS Therapies (OSTX) has 3 years of Preferred Stock Liabilities data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Preferred Stock Liabilities fell 77.69% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 77.69% YoY) and the FY2025 annual result came in at $1.1 million, down 73.74% from the prior year.
- Preferred Stock Liabilities steadied at $1.1 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $4.8 million in Q1 2025 to a low of $1.1 million in Q3 2025.
- A 3-year average of $2.3 million and a median of $1.4 million in 2025 frame the typical range for Preferred Stock Liabilities.
- Annual changes were most pronounced in 2025 — Preferred Stock Liabilities slumped 73.74% — and 2026, when it tumbled 77.69%.
- Tracing OSTX's Preferred Stock Liabilities over 3 years: stood at $4.1 million in 2024, then tumbled by 73.74% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
- The last three Preferred Stock Liabilities figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | OS Therapies | 19.31 Mn | 19.31 Mn | - | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Dec 31, 2024 | 4.08 Mn |